DRDO recently concluded a technology-transfer process for its indigenously developed Copper-Titanium technology to Pahwa MetalTech Private Limited ...
The Federation of Indian Chambers of Commerce and Industry today organized an innovation roundtable under the DRDO-FICCI Accelerated Technology ...
The Federation of Indian Chambers of Commerce and Industry today organized an innovation roundtable under the DRDO-FICCI Accelerated Technology ...
The default crisis of Greece will have marginal impact on software exports, an export promotion council official said on Thursday.
Pharma major Cipla's first quarter net profit surged 58% year-on-year to Rs 401 crore. The margin improvement was extremely healthy at around 27.6%. Pharma major Cipla's first quarter net profit surged 58% year-on-year to Rs 401 crore. The margin improvement was extremely healthy at around 27.6%.
A US District Court has ordered the seizure of a drug made by Cipla and sold by Velecra. S Radhakrishnan, CFO, Cipla has clarified on CNBC-TV18 that they are in process of filing an appeal within the next 60 days.
In an interview with CNBC-TV18, S Radhakrishnan, CFO, Cipla says, DEPB related income in FY11. He further says, the company will see marginal impact on earning per share (EPS), if the scheme is withdrawn.
In an interview with CNBC-TV18, S Radhakrishnan, Wholetime Director, Cipla, speaks about the results and gives his outlook going forward.
In an exclusive interview with CNBC-TV18’s Ekta Batra and Reema Tendulkar, S Radhakrishnan, Wholetime Director of Cipla denies rumours of any kind of stake sale, calling them ‘baseless’.